ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NBP / financials
KZIA (47) FHTX (18) BGM (37) SPRB (34) ⌘ Pro Terminal →

NovaBridge Biosciences (NBP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.01 -5.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.00

NovaBridge Biosciences (NBP) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $123.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NBP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NovaBridge Biosciences (NASDAQ: NBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.01 (-5.61% 1D, market cap $123.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NBP ranks #633 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NBP compare to KZIA and FHTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KZIA (Kazia Therapeutics Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $124.7M) and FHTX (Foghorn Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $126.5M). Among the 5-stock peer group, NBP leads on earnings multiple (N/A) while NBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NBP?
▼

Per NBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778016), NovaBridge Biosciences generated $264.0M in revenue (+83.3% YoY), -$46.3M in net income, and $0 in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 NBP TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $NBP, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $NBP R/R 2.2 : 1 • RQD 34/100 (E)
$NBP
Spot $1.01
1. GET IN (ENTRY)
$1.00–$1.02
2. HARD STOP (SUP)
$0.96 (-5.2%)
3. GET OUT (T1/T2)
$1.08 / $1.13
STOP-LOSS FLOOR (SUP $0.96): Hard stop sits 5.2% below spot to cap downside below key institutional support. If $NBP closes a daily candle below $0.96, step aside.
PROFIT TARGETS (RES $1.08 / $1.13): Scale out 50% at T1 (+6.5%) and trail stop to breakeven for T2 (+11.5%).
Want this $NBP sheet + Today's Top 3 Trades emailed free? Paper Trade $NBP →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $NBP Sheet
#1 • $MU R/R 3.2 : 1
Micron Technology, Inc.
IN
$108.50
STOP
$103.90
OUT
$117.50
#2 • 🔒 LOCKED R/R 3.4 : 1
AI Liquid-Cooling Leader
Target: +8.53% to +14.86% | Stop: -3.89%
#3 • 🔒 LOCKED R/R 3.1 : 1
Cash-Flow Buyback Machine
Target: +8.38% to +14.53% | Stop: -3.93%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.00 (-1.20%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 1.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE NBP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY NBP SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.1 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.28+7% Next Q
Q2 (-2Q)
39
Grade E$1.37-8% Next Q
Q3 (-1Q)
37
Grade E$1.26-19.8% Next Q
Current
34
Grade E$1.01-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NBP currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.47) and Max Pain ($1.06) forces dealer call-delta covering toward $5.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NBP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$3.5M (1.3% FCF Margin)
Revenue$264.0MGross Profit $137.3M (52%)Cost of Sales $126.7MOp Profit $0 (0%)OpEx (R&D/SG&A) $137.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $632.0K
FY24
Rev $144.0M
FY25
Rev $264.0M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$264.0M52%-35.7%-$46.3M-$44.0M-45%
FY 2024$144.0M52%-35.7%-$22.2M-$21.1M-30.6%
FY 2023$632.0K52%-80%-$207.7M-$183.8M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NBP)

  • ✓Walkthrough of NBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.56%▼ SUPPORT BREAKDOWN
2026-11-04O $1.19H $1.19L $1.01C $1.01VOL 1.07M
RES: $1.31SUP: $1.16🎯 Entry / Stop & Top 3 Trades ↑SMA50: $1.47SMA200: $2.15
$3.87$3.09$2.32$1.54$0.77RES $1.31SUP $1.16$1.012026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NBP Butterfly Map → + Track NBP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +83.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBP)

Health Care Rank #633 of 1015 ⚔️ KZIA vs NBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NBP vs. KZIA, FHTX, BGM, SPRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NovaBridge Biosciences (NBP) ranks #633 by composite RQD confidence (34/100, grade E) and #625 by equity capitalization ($123.5M). Within this direct 5-issuer industry benchmark cohort, NBP leads on earnings valuation at N/A trailing P/E, while NBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KZIA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NBP at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NBP ACTIVE
NovaBridge Biosciences
E 34/100 — — -35.0% -5.61% $123.5M Benchmark Subject
KZIA
Kazia Therapeutics Limited
D 47/100 — — — +0.75% $124.7M /kzia-vs-nbp →
FHTX
Foghorn Therapeutics Inc.
E 18/100 — — -35.0% 0.00% $126.5M /fhtx-vs-nbp →
BGM
BGM Group Ltd. (Class A)
D- 37/100 — 16.6% — 0.00% $127.4M /bgm-vs-nbp →
SPRB
Spruce Biosciences Inc.
E 34/100 — — -35.0% -3.91% $128.0M /sprb-vs-nbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001778016 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NovaBridge Biosciences (NBP) reported GAAP revenue of $264.0M (+83.3% vs. FY2024 revenue of $144.0M , and +41664.7% cumulative change since FY2023) , GAAP net income of -$46.3M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, NBP closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $264.0M -$46.3M — — $260.5M —
FY2024 (FY) 2024-12-31 $144.0M -$22.2M — — $212.7M —
FY2023 (FY) 2023-12-31 $632.0K -$207.7M -$183.8M -$183.8M — —

3. NBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NovaBridge Biosciences (NASDAQ: NBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.01 (-5.61% 1D, market cap $123.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NBP ranks #633 in composite RQD confidence.

How does NBP compare to KZIA and FHTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBP carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KZIA (Kazia Therapeutics Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $124.7M) and FHTX (Foghorn Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $126.5M). Among the 5-stock peer group, NBP leads on earnings multiple (N/A) while NBP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NBP?

Per NBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778016), NovaBridge Biosciences generated $264.0M in revenue (+83.3% YoY), -$46.3M in net income, and $0 in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NBP trading relative to its 50-day, 200-day, and 52-week technical levels?

NBP last traded at $1.01 (-5.61% on volume of 332,801 shares), positioning the stock -31.29% below its 50-day simple moving average ($1.47) and -53.02% below its 200-day simple moving average ($2.15). Across its 52-week range of $1.07 to $5.19, NBP sits at the 0.0% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

Direct Sub-Reports: NBP RQD Cockpit NBP 12M Forecast NBP Earnings & Move NBP Dividends & DRIP NBP Insiders & 13F NBP Whale Options NBP Profit Sankey NBP News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

NBP — NovaBridge Biosciences: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NovaBridge Biosciences (NBP) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.01 (-5.61% 1D, market capitalization $123.5M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NovaBridge Biosciences is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $0.1B.6M in FY 2023 indicates minimal or no current commercial revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NovaBridge Biosciences (NBP) reported $264.0M in annual revenue (up from $144.0M in FY2024, +83.3% YoY) and -$46.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($632.0K revenue, -$207.7M net income) through FY2025, NBP scaled operating cash flow to $0 and free cash flow to $0, backed by $260.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.07 – $5.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and a beta of 1.0.

  • Key Question #1: Can NBP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $264.0M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NBP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NovaBridge Biosciences (NBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NBP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NBP Bull vs. Bear Conversation Board — What's Your Call at $1.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NBP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NBP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.44 (+20.0%)
📌 Pinned Debate

Reported cash of $210.6M in FY 2025 exceeds the $139.6M market capitalization, and a GREEN-tagged exclusive-rights catalyst for VIS-102

Long NBP at $1.20 targeting $1.44. Reported cash of $210.6M in FY 2025 exceeds the $139.6M market capitalization, and a GREEN-tagged exclusive-rights catalyst for VIS-102 has been reported.. Institutional whale score is 3/20 and the risk/reward vs. the $1.15 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.20 and keeping dry powder in case we test $1.12.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.96 (-20.0%)
Spot @ $1.20

Valuation & margin reality check on NBP at $1.20 before chasing here

I respect the product at NovaBridge Biosciences, but the stock at $1.20 is a different story. Valuation & margin reality check on NBP at $1.20 before chasing here. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE